Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ELOX
Strong SellSinkerEloxx Pharmaceuticals, Inc. · Healthcare · United States · $52M · Avg Vol: $744K/d
15
StockRankGet insider-trade alerts
Q
26
V
48
M
22
P/E (TTM)
4.3x
ROE
—
D/E
0.3x
Dividend %
—
COMPANY DESCRIPTION
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-modulating drug candidates for rare genetic diseases caused by nonsense mutations. The company utilizes a proprietary platform to restore protein function, positioning itself as a developer of precision medicine for orphan indications.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 6.4M | 0 | — | — |
| EPS | — | -10.50 | -5.92 | -9.24 | -0.68 | — | 3.52 |
| Shares | 0.2M | 3.4M | 3.4M | — | 3.4M | +1644.9% | 3.4M |
| Debt | — | 13.4M | 4.0M | 6.5M | 1.0M | -57.9% | 11.8M |
| Equity | — | -10.7M | -22.6M | -24.3M | -11.9M | — | — |
| Op CF | — | -31.8M | -14.3M | -4.7M | -6.3M | — | -16.0M |
| Inv CF | — | -66.0K | 0.3M | 38.0K | 1.0K | — | — |
| Fin CF | — | 8.8M | -4.1M | 3.4M | 11.0M | — | — |
Loading 1Y...
PRICE (1Y)+22.4%
SMA 50SMA 200
Close
$16.28
RSI (14)
45.0
SCORE BREAKDOWN
Quality
26
ROIC (ROA)
-113.8%*5.6
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%38.0
FCF/Assets
—N/A
Piotroski
13.8
Int. Cover
-4.7x27.4
D/E Ratio
0.25x45.1
Current Ratio
3.74x63.6
Value
48
P/E (TTM)
4.3x98.1
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
1.3x78.3
P/S
—N/A
Div Yield
—N/A
Momentum
22
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-120%4.2
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$52M
P/E (Forward)
-21.1x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ELOX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ELOX | Eloxx Pharmaceuticals, Inc.(you) | $52M | 15 | Strong Sell |
| HYPD | Hyperion DeFi, Inc. | $51M | 16 | Strong Sell |
| INKT | MiNK Therapeutics, Inc. | $58M | 15 | Strong Sell |
| IMA | ImageneBio, Inc. | $61M | 15 | Strong Sell |
| SER | Serina Therapeutics, Inc. | $62M | 14 | Strong Sell |
| NTRB | Nutriband Inc. | $54M | 19 | Strong Sell |
| TIL | Instil Bio, Inc. | $51M | 9 | Strong Sell |
| HYFT | MindWalk Holdings Corp. | $65M | 14 | Strong Sell |
| MCRB | Seres Therapeutics, Inc. | $51M | 8 | Strong Sell |
| TCRX | TScan Therapeutics, Inc. | $51M | 7 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.1x · Gross margin 58.3%